These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12566095)

  • 1. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
    Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE
    Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice.
    Wroblewski VJ; McCloud C; Davis K; Manetta J; Micanovic R; Witcher DR
    Drug Metab Dispos; 2003 Apr; 31(4):502-7. PubMed ID: 12642478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of dendritic cell differentiation and maturation by decoy receptor 3.
    Hsu TL; Chang YC; Chen SJ; Liu YJ; Chiu AW; Chio CC; Chen L; Hsieh SL
    J Immunol; 2002 May; 168(10):4846-53. PubMed ID: 11994433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of Th1 response in decoy receptor 3 transgenic mice.
    Hsu TL; Wu YY; Chang YC; Yang CY; Lai MZ; Su WB; Hsieh SL
    J Immunol; 2005 Oct; 175(8):5135-45. PubMed ID: 16210617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
    Liu W; Ramagopal U; Cheng H; Bonanno JB; Toro R; Bhosle R; Zhan C; Almo SC
    Structure; 2016 Nov; 24(11):2016-2023. PubMed ID: 27806260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.
    Yu KY; Kwon B; Ni J; Zhai Y; Ebner R; Kwon BS
    J Biol Chem; 1999 May; 274(20):13733-6. PubMed ID: 10318773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
    Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
    Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
    Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M
    Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.
    Pitti RM; Marsters SA; Lawrence DA; Roy M; Kischkel FC; Dowd P; Huang A; Donahue CJ; Sherwood SW; Baldwin DT; Godowski PJ; Wood WI; Gurney AL; Hillan KJ; Cohen RL; Goddard AD; Botstein D; Ashkenazi A
    Nature; 1998 Dec; 396(6712):699-703. PubMed ID: 9872321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.
    Shen HW; Gao SL; Wu YL; Peng SY
    World J Gastroenterol; 2005 Oct; 11(38):5926-30. PubMed ID: 16273601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen.
    Matute-Bello G; Liles WC; Frevert CW; Dhanireddy S; Ballman K; Wong V; Green RR; Song HY; Witcher DR; Jakubowski JA; Martin TR
    J Infect Dis; 2005 Feb; 191(4):596-606. PubMed ID: 15655784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decoy receptor 3 regulates the expression of various genes in rheumatoid arthritis synovial fibroblasts.
    Fukuda K; Miura Y; Maeda T; Takahashi M; Hayashi S; Kurosaka M
    Int J Mol Med; 2013 Oct; 32(4):910-6. PubMed ID: 23912906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
    Lin WW; Hsieh SL
    Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.
    Wu YY; Chang YC; Hsu TL; Hsieh SL; Lai MZ
    J Biol Chem; 2004 Oct; 279(42):44211-8. PubMed ID: 15475369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.
    Kim S; Fotiadu A; Kotoula V
    Clin Immunol; 2005 Jun; 115(3):286-94. PubMed ID: 15893696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
    Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M
    Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor.
    Connolly K; Cho YH; Duan R; Fikes J; Gregorio T; LaFleur DW; Okoye Z; Salcedo TW; Santiago G; Ullrich S; Wei P; Windle K; Wong E; Yao XT; Zhang YQ; Zheng G; Moore PA
    J Pharmacol Exp Ther; 2001 Jul; 298(1):25-33. PubMed ID: 11408521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.
    Shi G; Wu Y; Zhang J; Wu J
    J Immunol; 2003 Oct; 171(7):3407-14. PubMed ID: 14500635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.
    Im J; Kim K; Hergert P; Nho RS
    J Pathol; 2016 Sep; 240(1):25-37. PubMed ID: 27218286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway.
    Chen PH; Yang CR
    J Immunol; 2008 Dec; 181(12):8441-9. PubMed ID: 19050262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.